COMPANY

Immunyx Pharma USA Inc.

immunyx.com ↗ · Mid-Atlantic

Status: Acquired, now part of IMMUNYX · How status works

Keywords: ulcerative colitis

Profile checked Oct 10, 2026

NIH awards 2

Annual award amounts. Total $2.0M.

Aug 5, 2026 NIH award 5R44DK145292-02 FY2026: $981,715 awarded for that fiscal year; activity R44 (SBIR); PI ENG, CHRISTINA; recipient as written: IMMUNYX PHARMA USA INC., NEW YORK, NY. Development of IMYX-3 for the Treatment of source ↗
Sep 10, 2025 NIH award 1R44DK145292-01 FY2025: $1,024,862 awarded for that fiscal year; activity R44 (SBIR); PI ENG, CHRISTINA; recipient as written: IMMUNYX PHARMA USA INC., NEW YORK, NY. Development of IMYX-3 for the Treatment source ↗

NIH award NIH awarded $982K (SBIR Phase II 5R44DK145292-02, continuation, notice Aug 5, 2026). NIH RePORTER 5R44DK145292-02 (Aug 5, 2026)
Evidence (1 event)
- Aug 5, 2026 · NIH RePORTER 5R44DK145292-02
  Organization: IMMUNYX PHARMA USA INC.; City/State: NEW YORK, NY; Project number: 5R44DK145292-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 981715; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of IMYX-3 for the Treatment of Ulcerative Colitis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals